ReviewAsthma research and practice2021
Biological therapy for severe asthma.
Review in Asthma research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab.Pediatric pulmonology · 2026Pooled it
- Impact of patient support programmes among patients with severe asthma treated with biological therapies: a systematic literature review and indirect treatment comparison.BMJ open respiratory research · 2024Pooled it
- Trial
- Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants.Drug design, development and therapy · 2023Trial
- Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Characteristics of Patients with Severe Uncontrolled Asthma in Saudi Arabia: A Cross-Sectional Study.Journal of asthma and allergy · 2026Article
- Breath-based stratification of asthma severity using the MISTRAL platform with integrated HScientific reports · 2025Article
- Biomarker-Associated Remission After Switching to Dupilumab in Severe Asthma Following Failure of Prior Biologics.Biomedicines · 2025Article
- Association of STAT6 gene polymorphism with atopic asthma among Yemeni children in Sana'a city, Yemen.BMC pediatrics · 2025Article
- Characteristics of Older Individuals with Asthma Being Treated with Biologics.Journal of asthma and allergy · 2025Article
- Preferences for Biologic Treatments: A Discrete Choice Experiment Survey of Canadians with Severe Asthma.Patient preference and adherence · 2025Article
- The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma.Journal of asthma and allergy · 2025Article
- Real-World Biologic Use Patterns in Severe Asthma, 2015-2021: The CLEAR Study.Pragmatic and observational research · 2025Article
- Assessment of Treatment Response in Patients With Severe Asthma Using Visual and Quantitative Analysis of Chest CT.Korean journal of radiology · 2024Article
- Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma.Advances in therapy · 2024Article
- Advancing Care in Severe Asthma: The Art of Switching Biologics.Advances in respiratory medicine · 2024Review
- Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.Handbook of experimental pharmacology · 2024Review
- Article
- miRNAs as Modern Biomarkers in Asthma Therapy.International journal of molecular sciences · 2023Review
- Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Around 5-10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is associated with increased mortality and hospitalization, increased health care burden and worse quality of life. In the last few years, new drugs have been launched and several asthma phenotypes according to definite biomarkers have been identified. In particular, therapy with biologics has revolutionized the management and the treatment of severe asthma, showing high therapeutic efficacy associated with significant clinical benefits. To date, four types of biologics are licensed for severe asthma, i.e. omalizumab (anti-immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), benralizumab (anti-IL-5 receptor a antibody) and dupilumab (anti-IL-4 receptor alpha antibody). The aim of this article was to review the biologic therapies currently available for the treatment of severe asthma, in order to help physicians to choose the most suitable biologic agent for their asthmatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.